Biomarin presents new data on the effect of long-term treatment with Voxzogo® (vosoritide) on arm span, bone health and growth in children with achondroplasia

BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2026 results. Revenue rose 19.9% year over year to $989.7 million and exceeded analysts’ estimates by 6.5%. Full-year revenue guidance was $3.9 billion at the midpoint, 0.7% above estimates. Non-GAAP adjusted EPS was $1.20, 26.6% above consensus. The stock rose 3.7% to $63.75.

BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 earningsrelease-6aug26ex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Second Quarter 2026 Financial and Operating Resul

BioMarin (BMRN) said the FDA accepted its supplemental NDA for VOXZOGO (vosoritide) to seek full approval for children with achondroplasia. The FDA set a PDUFA action date of Feb. 28, 2027. The filing relies on data from three ongoing studies measuring adult height and other growth outcomes. BMRN shares were $59.19, up 0.11% on the day.

BioMarin Pharmaceutical reported positive Phase 3 results for VOXZOGO in children with hypochondroplasia, meeting the primary endpoint and showing statistically significant improvement in annualized growth velocity, with safety consistent with achondroplasia. The company plans to submit a supplemental NDA to the FDA in Q3 and file with the EMA. H.C. Wainwright reiterated a Neutral rating and set a $50 target.

Morgan Stanley strategist Todd Castagno said companies that initiate regular quarterly dividends have historically outperformed: 650 basis points on average over six months and 1,000 basis points over 12 months after announcements, according to his note. He screened for “dividend hopefuls” with no current quarterly payout, net cash >5% of market cap, and free cash flow yield >5%. Examples: Centene (18% FCF yield), BioMarin (10.4% FCF yield; revenue guidance $3.825–$3.925B), Duolingo (user shortf

Realty Income (NYSE: O) says it began investing in data centers in late 2023 via a build-to-suit JV with Digital Realty, buying an 80% stake in an up to 48 MW facility. It also formed a hyperscale JV with Cloud Capital, targeting up to $1.4B investment for a 45% stake. Realty Income raised 2024 AFFO guidance to $4.44-$4.45/share and investment outlook to $10B.